2022
Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo
Bini J, Carson R, Cline G. Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo. Methods In Molecular Biology 2022, 2592: 61-74. PMID: 36507985, DOI: 10.1007/978-1-0716-2807-2_4.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2DopamineHumansPositron-Emission TomographyReceptors, Dopamine D2Receptors, Dopamine D3TetrabenazineVesicular Monoamine Transport ProteinsConceptsPositron emission tomographyBeta-cell massFunctional beta-cell massDopamine D2/D3 receptorsD2/D3 receptorsBeta-cell lossType 2 diabetesEfficacy of therapeuticsQuantitative positron emission tomographyInsulin secretionDopamine receptorsD3 receptorsGlucose regulationPET radioligandEmission tomographyType 1Clinical usePET imagingReceptorsQuantitative PET imagingVMAT2Cellular transportersImagingVivoQuantitative imaging
2020
Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder
Worhunsky PD, Angarita GA, Zhai ZW, Matuskey D, Gallezot JD, Malison RT, Carson RE, Potenza MN. Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder. Neuropsychopharmacology 2020, 46: 316-324. PMID: 33007778, PMCID: PMC7852666, DOI: 10.1038/s41386-020-00874-7.Peer-Reviewed Original ResearchMeSH KeywordsCocaineCognitionDefault Mode NetworkDopamineHumansReceptors, Dopamine D2Receptors, Dopamine D3ConceptsCocaine use disorderDMN suppressionDefault mode networkCognitive controlExecutive functioningStroop performanceCognitive control processesHealthy comparison participantsModerated-mediation analysisImproved task performanceStroop taskStimulant use disorderCognitive performanceTask performanceComparison participantsAddicted populationMode networkNetwork suppressionFMRI dataCUD participantsHC individualsMultimodal investigationControl processIndirect effectsD2R levelsSeparating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding
Smart K, Gallezot JD, Nabulsi N, Labaree D, Zheng MQ, Huang Y, Carson RE, Hillmer AT, Worhunsky PD. Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. NeuroImage 2020, 214: 116762. PMID: 32201327, PMCID: PMC7263955, DOI: 10.1016/j.neuroimage.2020.116762.Peer-Reviewed Original Research
2019
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.Peer-Reviewed Original ResearchConceptsT1DM individualsHealthy controlsDopamine DOutcome measuresAcute C-peptide responseSUVR-1Type 1 diabetes mellitusPET/CT scanningDuration of diabetesMaximal glycemic potentiationC-peptide responseClinical outcome measuresInsulin secretory capacityRoutine clinical measuresD3 receptor densityΒ-cell functionC-peptide releaseQuantitative PET measuresΒ-cell massDynamic PET scansQuantitative outcome measuresAgonist PET radioligandDiabetes mellitusReceptor agonistInsulin antibodies
2017
Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder
Worhunsky PD, Matuskey D, Gallezot JD, Gaiser EC, Nabulsi N, Angarita GA, Calhoun VD, Malison RT, Potenza MN, Carson RE. Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder. NeuroImage 2017, 148: 343-351. PMID: 28110088, PMCID: PMC5344702, DOI: 10.1016/j.neuroimage.2017.01.045.Peer-Reviewed Original Research